Upgrade to BuyandBill.com Pro to access this report and the complete suite of analytics tools.
| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| AstraZeneca PLC | ORPATHYS (savolitinib) + TAGRISSO (osimertinib) - (SAFFRON) | Non-small cell lung cancer (NSCLC) | Phase 3 | Ongoing | oral | Oncology |
| AstraZeneca PLC | DATROWAY (datopotamab deruxtecan) - (TROPION-Lung17) | Non-small Cell Lung Cancer (NSCLC) | Phase 3 | Ongoing | Intravenous | Oncology |
| AstraZeneca PLC | CIN-107 - (FigHTN-CKD) | Chronic Kidney Disease | Phase 2 | Ongoing | oral | N/A |
| AstraZeneca PLC | VEMIRCOPAN (ALXN2050) | Paroxysmal Nocturnal Hemoglobinuria | Phase 2 | Trial Discontinued | oral | Hematology |
| AstraZeneca PLC | Evusheld (AZD7442) - (PROVENT) | COVID-19 | Phase 3 | Withdrawn | Intramuscular | COVID-19 |
| AstraZeneca PLC | FASENRA (benralizumab) - (MESSINA) | Eosinophilic Esophagitis | Phase 3 | Data Released | Subcutaneous | Gastroenterology |
| AstraZeneca PLC | FASENRA (benralizumab) - (NATRON) | Hyper-eosinophilic syndrome (HES) | Phase 3 | Data Released | Subcutaneous | Immunology |
| AstraZeneca PLC | IMFINZI (durvalumab) - (CALLA) | Cervical cancer | Phase 3 | Trial Discontinued | Intravenous | Oncology |
